| Literature DB >> 34335523 |
Aklilu Feleke Haile1,2, Silvia Alonso3, Nega Berhe1, Tizeta Bekele Atoma4, Prosper N Boyaka5,6,7, Delia Grace8,9.
Abstract
Escherichia coli O157:H7 is an important foodborne pathogen but largely under investigated in Africa. The objectives of this study were to estimate the prevalence and pattern of antimicrobial resistance of E. coli O157:H7 in lettuce in Addis Ababa, Ethiopia. A total of 390 retail lettuce samples were collected across the 10 subcities of Addis Ababa. E. coli O157:H7 was isolated and identified following ISO-16654:2001 standard. The isolates were further tested for antimicrobial susceptibility to 13 antimicrobials using the Kirby-Bauer disk diffusion method. Out of the 390 lettuce samples examined, two (0.51%) carried E. coli O157:H7. The antimicrobial susceptibility pattern of strains showed resistance to ampicillin (100%) and tetracycline (50.0%). One of the two isolates was multidrug resistant to two antimicrobials tested. The results of this study demonstrate the presence of drug-resistant E. coli O157:H7 in lettuce in markets in Addis Ababa. Despite the low prevalence, its presence in a product that is eaten raw highlights potential public health risk in the area associated with this pathogen.Entities:
Keywords: Addis Ababa; Escherichia coli O157:H7; antimicrobial; lettuce; prevalence
Year: 2021 PMID: 34335523 PMCID: PMC8322604 DOI: 10.3389/fmicb.2021.694506
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Antibiotic disks used to test E. coli O157:H7 and their respective concentrations.
| No. | Antibiotic disks | Disk code | Concentration | Diameter of zone of inhibition in millimeter (mm) | ||
| Resistant ≤ | Intermediate | Susceptible ≥ | ||||
| 1 | Ampicillin | AM | 10 μg | 13 | 14–16 | 17 |
| 2 | Amoxycillin-clavulanic acid | AMC | 20/10 μg | 13 | 14–17 | 18 |
| 3 | Amikacin | AK | 30 μg | 14 | 15–16 | 17 |
| 4 | Ciprofloxacin | CIP | 5 μg | 15 | 16–20 | 21 |
| 5 | Ceftriaxone | CRO | 30 μg | 19 | 20–22 | 23 |
| 6 | Cefoxitin | FOX | 30 μg | 14 | 15–17 | 18 |
| 7 | Nitrofurantoin | F/M | 50 μg | 14 | 15–16 | 17 |
| 8 | Kanamycin | K | 30 μg | 13 | 14–17 | 18 |
| 9 | Nalidixic acid | NA | 30 μg | 13 | 14–18 | 19 |
| 10 | Sulfamethoxazole-trimethoprim | SXT | 25 μg | 10 | 11–15 | 16 |
| 11 | Tetracycline | TE | 30 μg | 11 | 12–14 | 15 |
| 12 | Streptomycin | S | 10 μg | 11 | 12–14 | 15 |
| 13 | Gentamicin | GM | 10 μg | 12 | 13–14 | 15 |
Prevalence of E. coli O157:H7 by risk factor.
| Risk factor | Number examined | Positive no (%) | χ2 | |||
| Sub-city | Addis Ketema | 39 | 0 | 8.041 | 9 | 0.530 |
| Akaki Kality | 39 | 0 | ||||
| Arada | 39 | 0 | ||||
| Bole | 39 | 1 (6.25) | ||||
| Gullele | 39 | 0 | ||||
| Kirkos | 39 | 0 | ||||
| Kolfe Keraneo | 39 | 0 | ||||
| Lideta | 39 | 0 | ||||
| Nefassilk | 39 | 0 | ||||
| Yeka | 39 | 1 (6.25) | ||||
Antimicrobial susceptibility pattern of E. coli O157:H7 isolates (n = 2).
| Antimicrobial use | Sensitive no. (%) | Intermediate no. (%) | Resistant no. (%) |
| Ampicillin (AM) | 0 (0) | 0 (0) | 2 (100) |
| Amoxicillin-clavulanate (AMC) | 2 (100) | 0 (0) | 0 (0) |
| Amikacin (AK) | 1 (50) | 1 (50) | 0 (0) |
| Ciprofloxacin (CIP) | 1 (50) | 1 (50) | 0 (0) |
| Ceftriaxone (CRO) | 2 (100) | 0 (0) | 0 (0) |
| Cefoxitin (FOX) | 2 (100) | 0 (0) | 0 (0) |
| Nitrofurantoin (F/M) | 1 (50) | 1 (50) | 0 (0) |
| Kanamycin (K) | 1 (50) | 1 (50) | 0 (0) |
| Nalidixic acid (NA) | 2 (100) | 0 (0) | 0 (0) |
| Sulfamethoxazole-trimethoprim (SXT) | 2 (100) | 0 (0) | 0 (0) |
| Tetracycline (TE) | 1 (50) | 0 (0) | 1 (50) |
| Streptomycin (S) | 1 (50) | 1 (50) | 0 (0) |
| Gentamicin (GM) | 1 (50) | 1 (50) | 0 (0) |